Navigation Links


HCV at Biology News

HCV at Biology Products
HCV at Biology Technology
HCV at Medicine News

HCV Spree in US

According to a nationwide study it was found that about 4.1 million people in the US are infected with hepatitis C virus (HCV). // The current rate of infection was found to be 1.6%. The Hepatitis C virus affects the liver and spreads through contact with contaminated blood products. Drug users suffer from a high risk of developing the disease. It is found to be an important factor for...

Obesity Makes Treatment of HCV Difficult

Research conducted by scientists at Mayo Clinic, Rochester, Minnesota has revealed that obesity was a metabolic condition, which could interfere //with the treatment for the Hepatitis C virus (HCV). Lead researcher Dr. Michael R. Charlton and his colleagues have found that obese patients treated for the chronic hepatitis C virus infection are also more likely to see better results whe...

HCV Patients Survival After Liver Transplantation is Not Improving

For liver transplant recipients without hepatitis C (HCV), survival has improved over time. However, for recipients with HCV, survival has not improved//, according to a study in the issue of Liver Transplantation. HCV-induced liver disease is the most common reason for liver transplantation in the U.S., however, previous studies have shown that these patients do not respond as well t...

HCV Patients Survival After Liver Transplantation is Not Improving

For liver transplant recipients without hepatitis C (HCV), survival has improved over time. However, for recipients with HCV, survival has not improved , according to a study in the issue of Liver Transplantation. HCV-induced liver disease is the most common reason for liver transplantation in the U.S., however, previous studies have shown that these patients do not respond as well...
HCV at Medicine Products

Procleix HIV-1/HCV Assay

Description:Donor Screening: The Procleix System has added a significant layer of a safety to the nation's blood supply. It utilizes innovative technologies developed by Gen-Probe including target capture, and a unique nucleic acid amplification technique called Transcription-Mediated Amplification (TMA).The Procleix HIV-1/HCV Assay can simultaneously detect the presence of HIV-1 and HCV in blood donor sa...
Company:Gen-Probe

VITROS® Anti-HCV Assay

Description:The VITROS Anti-HCV assay is the third diagnostichepatitis assay approved by the U.S. Food and DrugAdministration capable of being run in a randomaccess format on the VITROS ECi ImmunodiagnosticSystem with Intellicheck. Now the laboratory staffcan run an anti-HCV test anytime with the completemenu of more than 27 assays, and provide anti-HCVtest results in one hour or less....
Company:Ortho-Clinical Diagnostics

Anti-HCV Test

Description:AxSYM Anti-HCV (hepatitis C virus) is a Microparticle Enzyme Immunoassay (MEIA) for the qualitative detection of anti-HCV IgG to HCV recombinant proteins in human serum or plasma potassium EDTA, sodium EDTA, sodium heparin, lithium heparin, sodium citrate and potassium oxalate). Assay results, in conjunction with other laboratory results and clinical information, may be used to provide pres...
Company:Abbott Diagnostics

Worldwide HCV Performance Panel

Description:The Anti-HCV Mixed Titer Performance Panel consists of plasma specimens with reactivity ranging from weak to strong positive for antibodies to the Hepatitis C Virus. This Panel is intended for use by diagnostic manufacturers and clinical laboratories to evaluate their anti-HCV and RNA assays. Comprehensive data from all major test systems are included for comparative analysis on the well-cha...
Company:BBI Diagnostics

Anti-HCV Low Titer Performance Panel

Description:The Anti-HCV Low Titer Performance Panel consists of plasma specimens with reactivity ranging from weak to strong positive for antibodies to the Hepatitis C Virus. This Panel is intended for use by manufacturers and diagnostic laboratories to evaluate their anti-HCV assays. Comprehensive data from all major test systems are included for comparative analysis on the well-characterized specimen...
Company:BBI Diagnostics

More>>

HCV at Medicine Technology

Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting

REDWOOD CITY, Calif., May 02, 2007 /PRNewswire-FirstCall/ --Genelabs Technologies, Inc. announced today that a presentation wasmade today at the 20th International Conference on AntiviralResearch being held in Palm Springs, California, on anon-nucleoside hepatitis C virus (HCV) polymerase inhibitordiscovered by Genelabs. The oral presentation was given by Christopher D. Roberts,Ph...

Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment of HCV

A Unique Viral Kinetics Profile LAUSANNE, Switzerland, April 19, 2007 /PRNewswire/ -- DebiopharmGroup (Debiopharm), a global independent biopharmaceuticaldevelopment specialist in oncology and serious medical conditions,presented additional results of a previous phase Ib, 15 day studywith cyclophilin (Cyp) inhibitor Debio 025 in HIV/HCV (hepatitis Cvirus) co-infected patients. The data we...

Achillion Presents Positive Data on Novel Mechanism for Treating HCV at EASL Annual Meeting

-NS4A Antagonist Demonstrates Clinical Activity, a Novel Mechanismof Action and In Vitro Compatibility with other HCV Inhibitors- NEW HAVEN, Conn., April 16, 2007 /PRNewswire-FirstCall/ --Achillion Pharmaceuticals, Inc. today announced the presentation ofdata validating the clinical antiviral activity of one ofAchillion's NS4A antagonists, ACH-806, for the treatment ofhepatitis C virus (H...

ViroPharma Announces Presentation of Additional HCV-796 Data at Meeting of The European Association for the Study of the Liver

- Phase 1b Combination Data Highlight Favorable Tolerability andAdditive Antiviral Activity of HCV-796 - EXTON, Pa., April 13, 2007 /PRNewswire-FirstCall/ -- ViroPharmaIncorporated today announced additional data from a Phase 1b studyof HCV- 796, a unique, orally dosed hepatitis C virus (HCV)polymerase inhibitor at the 42nd Annual Meeting of the EuropeanAssociation for the Study of the Li...

New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders

Data to be Presented April 15th at EASL Conference in Barcelona,Spain VANCOUVER and SAN DIEGO, CA, April 11, 2007/PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developerof drugs for infectious diseases, has received new top-line resultsconfirming the previously announced clinical results (November 6,2006) indicating evidence of clinical benefit, safety andtolerability in a Phas...

More>>

Other TagsFragmentFragmentFragmentMicroscopicMicroscopicAptamerRetroviralRetroviralPlanktonVietnamCompoundCompoundCompoundCompoundGifts
(Date:9/5/2008)...TA, Sept. 5 /PRNewswire/ -- EthicAd, a nonprofit o...ough consumer education, announces,the launch of a...ic better,understand direct-to-consumer (DTC) adve... Smart About Prescription Drug Advertising," is,ho...esearch and was,developed by the FDA in partnershi...
(Date:9/5/2008)...ton, DCWomen with hormone-receptor positive, metas... to help keep their cancer at bay, but when the tu...tment with chemotherapy becomes the only option. B... Cancer Symposiummay change this approach. Early ...sitize" the tumor, allowing anti-hormonal drugs to...
(Date:9/4/2008)...ork, NY, September 5, 2008Private Medicare Advanta... more per enrollee in 2008 compared to what the sa...icare fee-for-service program, according to a new ...yment reductions to MA plans mandated by the Medic... 2008 (MIPPA) scheduled to take effect beginning ...
(Date:9/4/2008)... want stronger labeling about fungal infection ris...) -- Federal health authorities have asked the man...rugs to bolster safety warnings on the risk of dev...drugs, Humira, Cimzia, Enbrel and Remicade, belong... factor alpha blockers (TNF-alpha blockers), which...
Breaking Medicine News(10 mins):Health News:Prescription Drug Advertising Subject of New FDA Web Site for Consumers 2Health News:1 step back ... 2 steps forward 2Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3
(Date:9/5/2008)...eeding colonies of a critically endangered vulture...s of millions to a few thousand, are too small to ...of Michigan analysis shows. , Adding wild birds ...ndia, is crucial, but political and logistical bar... A. Johnson. , The study was published online Au...
(Date:9/5/2008)...of Hurricane Gustav is shown via a sequence of sat...ion Imaging Spectrometer (MERIS) instrument on 25 ...(from right to left). , Gustav formed on 25 Augu...aiti (seen above far right image), when a tropical...e feature (visible), causing the U.S. National Hur...
(Date:9/5/2008)...le in French and Spanish . , Researchers fro...Bromatology and Department of Chemistry-Physics ... study in which they have revealed the need of cou...n who follows Ramadan. , According to the collec...sumption levels are not appropriate if compared wi...
(Date:9/4/2008)... M.D. Anderson Cancer Center have developed a risk...y for African Americans that suggests a greater ri...D), according to a report published in the Septemb...l of the American Association for Cancer Research....African Americans with lung cancer and 497 African...
Breaking Biology News(10 mins):Recovery efforts not enough for critically endangered Asian vulture 2Recovery efforts not enough for critically endangered Asian vulture 3Hurricane Gustav 2Nutritionists of the UGR suggest diet improvements during Ramadan 2African-Americans have unique lung cancer risks from chronic obstructive pulmonary disease 2Cavidi Signs Agreement With the Clinton Foundation HIV AIDS Initiative to Lower Costs of HIV Monitoring 7267 1Cavidi Signs Agreement With the Clinton Foundation HIV AIDS Initiative to Lower Costs of HIV Monitoring 7267 2Cavidi Signs Agreement With the Clinton Foundation HIV AIDS Initiative to Lower Costs of HIV Monitoring 7267 3Cell Therapeutics Inc Announces 246 5 Million Offering 7264 1Cell Therapeutics Inc Announces 246 5 Million Offering 7264 2Cell Therapeutics Inc Announces 246 5 Million Offering 7264 3Trojan 28R 29 and the National Sexuality Resource Centers Campaign for Sexual Literacy Recognize Outstanding College Reporting on Sexual Health 952 1Trojan 28R 29 and the National Sexuality Resource Centers Campaign for Sexual Literacy Recognize Outstanding College Reporting on Sexual Health 952 2Trojan 28R 29 and the National Sexuality Resource Centers Campaign for Sexual Literacy Recognize Outstanding College Reporting on Sexual Health 952 3Trojan 28R 29 and the National Sexuality Resource Centers Campaign for Sexual Literacy Recognize Outstanding College Reporting on Sexual Health 952 4AIDS Action Council Statement on World AIDS Day 2007 3A Leadership Needed for a National Strategy to Stop the AIDS Epidemic 949 1AIDS Action Council Statement on World AIDS Day 2007 3A Leadership Needed for a National Strategy to Stop the AIDS Epidemic 949 2
Other Contentsangiographyangiographyangiographyangiographyfluoresceinfluoresceinfluoresceinfluoresceinfolicfolicfolicfolatefolatefontanellesadditivesadditivesadditivesadditivesadditivesguideguideguideguideguideguideguideguideguidefracturesfracturesfracturesfractures